Nelfinavir

Antiviral Agents
Impact of Human Immunodeficiency Virus Type 1 Subtype C on Drug Resistance Mutations in Patients from Botswana Failing a Nelfinavir-Containing Regimen
Florence Doualla-Bell, Ava Avalos, Tendani Gaolathe, Madisa Mine, Simani Gaseitsiwe, Ndwapi Ndwapi, Vladimir A. Novitsky, Bluma Brenner, Maureen Oliveira, Daniella Moisi, Howard Moffat, Ibou Thior, Max Essex, Mark A. Wainberg
Clinical Therapeutics
Pregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 Women
Déborah Hirt, Jean-Marc Treluyer, Vincent Jullien, Ghislaine Firtion, Hélène Chappuy, Elisabeth Rey, Gérard Pons, Laurent Mandelbrot, Saïk Urien
Clinical Therapeutics
Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children
Déborah Hirt, Saïk Urien, Vincent Jullien, Ghislaine Firtion, Elisabeth Rey, Gérard Pons, Stéphane Blanche, Jean-Marc Treluyer
Pharmacology
Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate
Marta Boffito, Anton Pozniak, Brian P. Kearney, Christopher Higgs, Anita Mathias, Lijie Zhong, Jaymin Shah
Clinical Therapeutics
Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors
Patrick F. Smith, Gregory K. Robbins, Robert W. Shafer, Hulin Wu, Song Yu, Martin S. Hirsch, Thomas C. Merigan, Jeong-Gun Park, Alan Forrest, Margaret A. Fischl, Gene D. Morse, the ACTG 384-5006 Team
Antiviral Agents
Role of P-Glycoprotein in Distribution of Nelfinavir across the Blood-Mammary Tissue Barrier and Blood-Brain Barrier
Jeffrey E. Edwards, Jane Alcorn, Juoko Savolainen, Bradley D. Anderson, Patrick J. McNamara
Pharmacology
Bayesian Parameter Estimates of Nelfinavir and Its Active Metabolite, Hydroxy-tert-Butylamide, in Infants Perinatally Infected with Human Immunodeficiency Virus Type 1
Salomé Payen, Albert Faye, Alexandra Compagnucci, Carlo Giaquinto, Diana Gibbs, Roberto Gomeni, Françoise Bressolle, Evelyne Jacqz-Aigrain
Antiviral Agents
Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects
Mario Regazzi, Renato Maserati, Paola Villani, Maria Cusato, Patrizia Zucchi, Elena Briganti, Rinaldo Roda, Luca Sacchelli, Francesca Gatti, Palma Delle Foglie, Giulia Nardini, Paolo Fabris, Fernanda Mori, Paula Castelli, Lucia Testa
Pharmacology
Potential for Interactions between Caspofungin and Nelfinavir or Rifampin
Julie A. Stone, Elizabeth M. Migoya, Lisa Hickey, Gregory A. Winchell, Paul J. Deutsch, Kalyan Ghosh, Amanda Freeman, Sheng Bi, Rajesh Desai, Stacy C. Dilzer, Kenneth C. Lasseter, Walter K. Kraft, Howard Greenberg, Scott A. Waldman
Antiviral Agents
Impact of Nelfinavir Resistance Mutations on In Vitro Phenotype, Fitness, and Replication Capacity of Human Immunodeficiency Virus Type 1 with Subtype B and C Proteases
Luis M. F. Gonzalez, Rodrigo M. Brindeiro, Renato S. Aguiar, Helena S. Pereira, Celina M. Abreu, Marcelo A. Soares, Amilcar Tanuri

Main menu

User menu

Search

Nelfinavir

Pages